Guide
Breed-Specific Adverse Event Risks
Why breed matters in medication safety, what size and genetics have to do with drug reactions, and how to interpret PlainBreed data for your pet.
Key Takeaway
PlainBreed tracks 506 breeds across 53 species. Breed-specific adverse event patterns emerge from three factors: popularity (popular breeds accumulate more reports), body size (affects dosing margins and metabolism), and genetics (mutations like MDR1 make some breeds hypersensitive to specific drug classes). Use report rates and serious-outcome percentages, not raw counts, to compare breeds meaningfully.
Why Breed Appears in Medication Safety Data
The FDA's openFDA adverse event reports include breed data when available, which creates a database that can reveal patterns specific to particular breeds, species, or size categories. Over 1 million reports in PlainBreed's database contain some form of breed identification, covering everything from Labrador Retrievers and Beagles to less common breeds like Akitas and Rhodesian Ridgebacks.
Breed matters for medication safety for reasons that go beyond simple frequency. Different breeds have different metabolic rates, body compositions, and, critically, genetic variants that affect how they process drugs. A medication dose calibrated for a typical 30-pound mixed-breed dog may be appropriate, insufficient, or dangerously high for a 30-pound dog of a specific breed depending on that breed's pharmacokinetic profile.
You can explore breed-specific data directly on PlainBreed's breeds directory, which shows total reports, most common reactions, and serious outcome rates for each breed in the database.
Popularity vs. Sensitivity: Reading the Data Correctly
The most common mistake when reading breed-level adverse event data is treating raw report counts as a direct measure of risk. Labrador Retrievers consistently appear near the top of almost every adverse event ranking, not because they are especially sensitive to medications, but because they are one of the most popular dog breeds in the United States. More Labradors receive medications; more Labrador reports are submitted.
The more meaningful metric is the proportion of serious outcomes. If a breed has 10,000 reports and 3% result in death or life-threatening events, that's a different risk signal than a breed with 500 reports and 20% serious outcomes. PlainBreed surfaces both figures for each breed profile so you can make this comparison directly.
Similarly, when examining which drugs appear most in reports for a given breed, consider whether those drugs are commonly prescribed for that breed's health issues. Drugs used for conditions prevalent in a specific breed will naturally accumulate more reports for that breed, regardless of any special sensitivity.
Body Size, Weight, and Drug Dosing
Body weight is the primary variable used to calculate drug doses in veterinary medicine. Most medications are prescribed in milligrams per kilogram (mg/kg), and the therapeutic window, the range between an effective dose and a toxic dose, can be narrow in smaller animals. A dosing error that is inconsequential in a 70-pound dog may be life-threatening in a 7-pound toy breed.
Beyond simple weight scaling, smaller animals often have proportionally larger livers and kidneys relative to body mass, which can affect how quickly drugs are metabolized and excreted. This means drugs may clear faster in smaller breeds, requiring more frequent dosing for effectiveness, but the same rapid clearance can sometimes make toxic metabolites accumulate differently.
Giant breeds face the opposite challenge. Their slower metabolism means some drugs stay active longer, and certain drug classes, particularly non-steroidal anti-inflammatory drugs (NSAIDs) commonly prescribed for joint pain in large breeds, carry elevated risks of gastrointestinal and kidney complications when used long-term. The adverse event data for GI and renal reactions reflects this pattern clearly.
Genetic Drug Sensitivities by Breed
Some breed-specific drug risks are not about dosing at all, they stem from inherited genetic variants that alter how an individual animal processes certain compounds. The most clinically significant example in dogs is the MDR1 gene mutation (also called the ABCB1 mutation).
The MDR1 Mutation
The MDR1 gene encodes a protein that acts as a drug pump in the blood-brain barrier, preventing certain substances from entering the brain. Dogs with a mutation in this gene cannot effectively pump specific drugs out of the central nervous system. At doses that are safe for most dogs, MDR1-mutant dogs can experience severe, sometimes fatal, neurological toxicity.
Breeds with high prevalence of the MDR1 mutation include:
- Australian Shepherd (approximately 50% carry at least one copy)
- Rough and Smooth Collie (approximately 70%)
- Shetland Sheepdog (approximately 15%)
- Old English Sheepdog
- Border Collie
- McNab Shepherd
- Long-haired Whippet
Drugs to use with particular caution in MDR1-susceptible breeds include ivermectin (at antiparasitic doses), loperamide (the active ingredient in Imodium), certain chemotherapy agents, and some sedatives. Washington State University's Veterinary Clinical Pharmacology Lab offers genetic testing through your veterinarian.
Other Known Breed Sensitivities
Beyond MDR1, other documented breed-specific sensitivities include: Greyhounds and similar sighthounds, which metabolize barbiturate anesthetics unusually slowly due to low body fat and different liver enzyme profiles; Brachycephalic breeds (Bulldogs, Pugs, Boston Terriers), which carry elevated anesthesia risks related to their airway anatomy; and Doberman Pinschers, which are predisposed to dilated cardiomyopathy and may have different responses to cardiac medications. Always discuss your pet's breed with the prescribing veterinarian before procedures or new medications.
Using PlainBreed Data Effectively
PlainBreed's breed profiles show total reports, average age at reporting, death rate, and the top reactions and drugs associated with each breed. To get the most from this data:
- Search for your pet's specific breed. If it's a mixed breed, consider the dominant breed components.
- Note the serious outcome percentage alongside total reports. This gives a better sense of risk than counts alone.
- Review the top drugs listed for your breed and cross-reference any your pet has been prescribed or may be prescribed.
- Look at the top reactions for your breed and ask your veterinarian if any are associated with planned medications.
- If your pet is in a herding breed, discuss MDR1 genetic testing with your veterinarian before any drug that appears on the known sensitivity list.
Frequently Asked Questions
Why do some breeds have far more adverse event reports than others?
Report volume is heavily influenced by breed popularity. Breeds like Labrador Retrievers and German Shepherds are among the most common in the U.S., so they naturally appear in more reports simply because more of them are prescribed medications. When comparing breeds, look at the rate of serious outcomes (deaths and life-threatening events as a percentage of total reports) rather than raw report counts. A rare breed with a high serious-outcome rate may indicate genuine sensitivity.
Do smaller dogs really react differently to drugs than larger dogs?
Yes, body weight is one of the most significant factors in drug dosing and sensitivity. Many veterinary drugs are dosed by weight (mg/kg), and the margin between therapeutic and toxic doses can narrow significantly in smaller animals. Additionally, toy and miniature breeds may have proportionally higher body surface areas relative to weight, affecting how quickly drugs are metabolized and eliminated. This is why standard doses listed on labels often specify per-pound or per-kilogram ranges.
Which breeds are known to have genetic drug sensitivities?
The MDR1 (ABCB1) gene mutation is the most studied genetic drug sensitivity in dogs. Breeds commonly carrying this mutation include Australian Shepherds, Collies, Shetland Sheepdogs, Old English Sheepdogs, and several other herding breeds. Dogs with this mutation may be unable to pump certain drugs, including ivermectin, loperamide, and some chemotherapy agents, out of the brain, leading to severe neurological toxicity at doses tolerated by other breeds. Genetic testing is available through veterinary labs.
Are purebred dogs at higher risk than mixed breeds?
The adverse event database captures breed data as reported, and purebred dogs are more consistently identified by breed. Mixed breeds are often listed simply as "mixed breed" or left unspecified, making comparisons difficult. Some genetic conditions, like the MDR1 mutation in herding breeds, are more predictable in purebreds because breeding lines are better documented. However, mixed-breed dogs that inherit risk alleles from a susceptible parent breed can carry the same sensitivity.
Does breed size predict which reactions are most likely?
Body size correlates with certain reaction patterns, but the relationship is not simple. Large and giant breeds are more often represented in musculoskeletal and joint medication reports, reflecting the higher prevalence of orthopedic conditions in those breeds. Small breeds tend to appear more in reports involving dental medications and anesthesia. Neurological reactions to isoxazoline flea medications have been documented across all size categories, with no consistent size predisposition identified.
How should I use PlainBreed data when talking to my vet?
PlainBreed data is most useful as a starting point for questions, not as a basis for refusing treatment. If your dog is an Australian Shepherd and your vet recommends a drug that appears frequently in adverse event reports for that breed, you can ask specifically whether MDR1 testing is appropriate before dispensing. If a drug has a high rate of serious outcomes in your pet's species, ask your vet to compare it against alternatives. Bring specific data, report counts, reaction types, outcome rates, rather than general concerns.
Sources
- U.S. FDA openFDA, Animal & Veterinary Adverse Events API (api.fda.gov/animalandveterinary)
- Washington State University Veterinary Clinical Pharmacology Lab, MDR1 Gene Mutation in Dogs
- FDA Center for Veterinary Medicine, Animal Adverse Events (fda.gov/animal-veterinary)
- Journal of Veterinary Pharmacology and Therapeutics, MDR1 Pharmacogenomics in Dogs
- PlainBreed database, 506 breeds, 53 species, 1M+ reports (openFDA source)
This content is for informational purposes only and does not constitute veterinary advice. Consult your veterinarian about your pet's medications.
The live report counts and ratios linked from this guide are rendered directly from FDA openFDA adverse event data. Worked examples and illustrative numbers cited in the guide text are for explaining the method, not drawn from this portal's live database. This page's data-linked figures draw directly on FDA openFDA data. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.
Frequently asked questions
Where does this data come from?
Every figure derives from the U.S. FDA Center for Veterinary Medicine (CVM) animal drug adverse event reporting program, accessed through the openFDA animal & veterinary endpoint. We use no proprietary aggregators and no estimated data, see the methodology page for the exact source and extract date.
Do these reports prove a medication is dangerous?
No. Adverse event reports are voluntary and unverified. A report means only that someone observed a health event after a product was used, it does not establish that the product caused it. Always consult your veterinarian before starting, changing, or stopping any medication.
Why does one breed have far more reports than another?
Report volume is driven mostly by how common a breed is and how actively its owners and veterinarians file reports. A popular breed such as the Labrador Retriever sits near the top because the breed is enormous in number, not because it faces unusual risk.
How often is the data updated?
We refresh from the FDA CVM extract periodically. The current extract date is shown on the methodology page.